| Clinical and laboratory findings | T.SPOT positive () | T.SPOT negative () | value |
| Age, years, mean ± SD | | | 0.002 | Patients with risk factors for LTBI, (%) | 1 (20) | 8 (9.2) | 0.41 | SLE disease duration SLE, median (IQR) | 174 (135–357) | 126 (60–207) | 0.10 | SLEDAI, mean ± SD | | | 0.43 | SLICC, median (IQR) | 0 (0–0.75) | 0 (0-1) | 0.53 | dsDNAn, UI/mL, median (IQR) | 13.70 (2.05–33) | 14.50 (3.72–45.50) | 0.65 | Daily prednisone > 7.5 mg, (%) | 1 (20) | 17 (19.5) | 0.53 | Immunosuppressed patients, (%) | 2 (40) | 57 (65.5) | 0.56 | Hydroxychloroquine treatment, (%) | 4 (80) | 75 (86.2) | 0.54 | Steroid dose, mg, mean ± SD | | | 0.67 | Steroid cumulative dose, mg, mean ± SD | | | 0.94 | Cumulative steroids/duration of disease, mg/year, mean ± SD | | | 0.40 | Mycophenolate dose, mg, mean ± SD | | | 0.88 | Mycophenolate cumulative dose, mg, mean ± SD | | | 0.001 | Cumulative mycophenolate/disease duration, mg/year, mean ± SD | | | 0.001 | Methotrexate dose, mg, mean ± SD | 0 | | 0.38 | Methotrexate cumulative dose, mg, mean ± SD | | | 0.77 | Cumulative methotrexate/disease duration, mg/year, mean ± SD | | | 0.42 |
|
|